Western tradition · mTOR inhibitor · prescription

Rapamycin (Sirolimus) 雷帕霉素

The single most reproducible lifespan-extending molecule in animals — a prescription drug under off-label longevity study.

2,394ClinicalTrials.gov matched
2132PubMed RCT records
656Meta-analysis records
379+PubMed records
Rapamycin / sirolimusKey active compound

Data definition. Matched records include all indexed medical endpoints for this intervention — not only longevity. Longevity-relevant records are screened separately and cited in the evidence summary below. Counts are matched-record volumes, not de-duplicated trials and not efficacy claims.

Origin & tradition

Not a supplement: rapamycin is an FDA-approved immunosuppressant/mTOR inhibitor now studied off-label for aging.

Why longevity buyers care

Key active: Rapamycin / sirolimus (mTOR inhibitor).

mTOR inhibition extends lifespan across yeast, worms, flies, and mice more reproducibly than any other intervention; human longevity use is off-label and dosing/safety (the PEARL trial and others) is the open question.

Effect summary

Studied health outcomes

Editorial summary — This table is curated by hand from published research consensus, not automatically calculated from our trial database. Grades reflect our interpretation of the literature. Treat as a starting point, not a definitive verdict. See the Evidence panel below for the underlying trial and paper counts sourced directly from ClinicalTrials.gov and PubMed.
Health outcomeEffectMagnitudeGrade
mTORC1 inhibition (autophagy induction)↑IncreasesStrongA
Lifespan (mouse models) — Most replicated mammalian lifespan result; 9–14% increase at mid-life dosing↑IncreasesStrongA
Immune function / infection risk — Dose-dependent; lower intermittent doses may have less immunosuppression↓DecreasesModerateB
Insulin sensitivity — Risk at higher doses; intermittent low doses may not impair↓DecreasesMinorB
Cardiac function (older adults)↑IncreasesModerateB

Grade: A = robust RCTs · B = several RCTs / meta-analysis · C = limited or mixed RCTs · D = observational or early data

Dosage guidance

How Rapamycin (Sirolimus) is typically used

Prescription medication — requires a licensed prescriber. Not a supplement.
Typical dose
1–6 mg/week (intermittent, off-label longevity use)
Form
tablet (prescription only — sirolimus)
Timing
once weekly, same day each week

PRESCRIPTION ONLY. Not a supplement. Used in longevity medicine off-label; prescribed protocols vary (1mg–10mg/week). Clinical use at daily doses (up to 40mg) for organ transplant rejection. Longevity-specific dosing based on emerging data from the ITP and physician protocols (Attia, Green).

Informational only — not a prescription or personalised medical advice. Consult a qualified clinician before starting any supplement or medication.

Evidence summary

What the research actually says

75Evidence confidence
Extensive human-trial evidence2,132 randomized controlled trials · 656 meta-analyses / systematic reviews

Gold-standard animal lifespan data; human longevity off-label, early

mTOR inhibition extends lifespan across yeast, worms, flies, and mice more reproducibly than any other intervention; human longevity use is off-label and dosing/safety (the PEARL trial and others) is the open question.

2,394registered clinical trials reference this intervention
    3selected from 379+ PubMed papers (longevity / aging angle)
    Key active: Rapamycin / sirolimus (mTOR inhibitor).

    According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-11-16. They include trials across many endpoints, not only longevity.

    Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.

    Suppliers

    No Rapamycin (Sirolimus) suppliers listed yet

    Tell us what you need and we will source suppliers for you.

    Request sourcing help